Effects on Syngeneic Tumors of F&lt;sub&gt;1&lt;/sub&gt; Lymphocytes Sensitized in vitro by Parental Stimulator Cells

Havelaar, Ian J.; McCullough, Christopher; Sugarbaker, Paul H.

doi:10.1159/000226027

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The con sistently high levels of cytotoxicity to EL-4 with B6AFi-anti BL/6 responses were due to Fi lym phocyte sensitization by parental stimulator cells. This was a phenomenon previously investigated by Havelaar et al [13].…”

Section: Alloantigen-activated Lysis O F Tumor Andmentioning

confidence: 54%

Alloantigen-Activated Lysis of Syngenic Tumor Augmented by Allogenic Lymphocytes as Cold Targets

Sugarbaker¹,

Matthews²

1985

Oncology

Self Cite

View full text Add to dashboard Cite

In the past, most work in tumor immunology involved attempts to demonstrate tumor-specific transplantation antigens; however, recent in vitro work has shown that it is not necessary to sensitize to a specific tumor antigen to achieve lysis of syngenic tumor cells. Responder spleen cells from B6AF₁ mice (H-2^a_’^b) were sensitized in mixed lymphocyte cultures (MLC) to alloantigens on spleen cells from B10.D2 (H-2^d) mice. In cell-mediated lympholysis (CML) assays the relevant allogenic P815 (H-2^d) tumor targets and B10.D2 lymphoblast targets were lysed. In addition, the semisyngenic tumor target EL-4 (H-2^b) was lysed but RDM-4 (H-2^k) was not. B10.BR (H-2^k), C57BL/6 (H-2^b) and B6AF₁ lymphoblasts were not lysed. If lymphocytes were added as cold targets to the CML assay, B10.D2 lymphocytes completely absorbed lytic activity when B10.D2 lymphoblasts were the target. If B10.D2 lymphocytes were added when P815 was the target, lysis was reduced but could not be abolished. When B10.D2 lymphocytes were added with EL-4 as a target, lysis doubled. These experiments show that the neoplastic determinant on tumor cells recognized by alloantigen-activated lymphocytes does not cross-react with stimulator cell alloantigen and is not an alien histocompatibility antigen. These observations should be considered when in vivo attempts are made to control tumor with in vitro activated lymphocytes; transfer of not only in vitro activated cells but also allogenic stimulator cells to the tumor site may be necessary for maximal tumor destruction.

show abstract

Section: Alloantigen-activated Lysis O F Tumor Andmentioning

confidence: 54%

Alloantigen-Activated Lysis of Syngenic Tumor Augmented by Allogenic Lymphocytes as Cold Targets

Sugarbaker¹,

Matthews²

1985

Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells

Ottow

Eggermont

Steller

et al. 1987

Cancer

View full text Add to dashboard Cite

In a significant proportion of patients with gastrointestinal and ovarian malignancy the peritoneal cavity is a prominent site at which surgical treatment fails. Adjuvant treatments directed at this site should be investigated in an attempt to improve survival in patients with these cancers. In the study reported here, a model of intraperitoneal tumor in the mouse was established and shows the effectiveness of lympho-kine activated killer (LAK) cells and exogenous interleukin-2 (IL-2) in the control of intraperitoneal tumor. A standard regimen was used to treat seven different tumors in three different mouse strains. In all seven cases a significant reduction in the intraperitoneal tumor mass was observed when LAK cells plus IL-2 were used as immunotherapy. A prolonged survival was also demonstrated in mice with intraperitoneal tumor. The relevance of these observations to patients with cancer was demonstrated in that allogeneic and syngeneic LAK cells were equally effective, LAK cells generated from normal and from tumor-bearing donors showed equal reactivity, and this treatment was successful in the immuno-compromised host. Both IL-2 derived from an IL-2-producing subline of the EL-4 thymoma and recombinant IL-2 were equally effective in the control of intraperitoneal tumor. The local-regional effects of the intraperitoneal administration of 1L-2 were demonstrated by high levels of LAK cell cytotoxicity in peritoneal exudate cells. Intraperitoneal IL-2 or IL-2 plus LAK cell regimens should be investigated in the treatment of malignancy that spreads by implantation onto peritoneal surfaces.

show abstract

Effects on Syngeneic Tumors of F<sub>1</sub> Lymphocytes Sensitized in vitro by Parental Stimulator Cells

Cited by 2 publications

References 6 publications

Alloantigen-Activated Lysis of Syngenic Tumor Augmented by Allogenic Lymphocytes as Cold Targets

Alloantigen-Activated Lysis of Syngenic Tumor Augmented by Allogenic Lymphocytes as Cold Targets

The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells

Contact Info

Product

Resources

About